Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options
2024 ASCO Annual Meeting
Milana Bergamino Sirvén, MD, PhD, of Spain’s Institute of Cancer Research, discusses her findings on molecular profiling of patients with estrogen receptor–positive, HER2-positive early-stage breast tumors after short-term preoperative endocrine therapy. This study suggests that such profiling may help clinicians identify those patients with a favorable prognosis for adjuvant endocrine therapy and those who may require additional treatment (Abstract 560).
The ASCO Post Staff
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).
The ASCO Post Staff
Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).
The ASCO Post Staff
Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).
The ASCO Post Staff
Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with functional high-risk multiple myeloma; and DREAMM-7 on belantamab mafodotin-blmf plus bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory disease.
The ASCO Post Staff
Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).
